Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120


Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.

Pei Y, Mercier RW, Anday JK, Thakur GA, Zvonok AM, Hurst D, Reggio PH, Janero DR, Makriyannis A.

Chem Biol. 2008 Nov 24;15(11):1207-19. doi: 10.1016/j.chembiol.2008.10.011.


CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches.

Ortega-Gutiérrez S, López-Rodríguez ML.

Mini Rev Med Chem. 2005 Jul;5(7):651-8. Review.


Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands.

Raitio KH, Salo OM, Nevalainen T, Poso A, Järvinen T.

Curr Med Chem. 2005;12(10):1217-37. Review.


Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.

Ashton JC, Wright JL, McPartland JM, Tyndall JD.

Curr Med Chem. 2008;15(14):1428-43. Review.


Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor.

Zhang Y, Xie Z, Wang L, Schreiter B, Lazo JS, Gertsch J, Xie XQ.

Int Immunopharmacol. 2011 Sep;11(9):1303-10. doi: 10.1016/j.intimp.2011.04.013. Epub 2011 May 1.


The effects of charge-neutralizing mutation D6.30N on the functions of CB1 and CB2 cannabinoid receptors.

Nebane NM, Kellie B, Song ZH.

FEBS Lett. 2006 Oct 2;580(22):5392-8. Epub 2006 Sep 12.


The second intracellular loop of the human cannabinoid CB2 receptor governs G protein coupling in coordination with the carboxyl terminal domain.

Zheng C, Chen L, Chen X, He X, Yang J, Shi Y, Zhou N.

PLoS One. 2013 May 7;8(5):e63262. doi: 10.1371/journal.pone.0063262. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/11146424-f236-4fc6-85b2-cd393cfb6a94.


Mastering tricyclic ring systems for desirable functional cannabinoid activity.

Petrov RR, Knight L, Chen SR, Wager-Miller J, McDaniel SW, Diaz F, Barth F, Pan HL, Mackie K, Cavasotto CN, Diaz P.

Eur J Med Chem. 2013 Nov;69:881-907. doi: 10.1016/j.ejmech.2013.09.038. Epub 2013 Sep 29.


Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.

Montero C, Campillo NE, Goya P, Páez JA.

Eur J Med Chem. 2005 Jan;40(1):75-83.


Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.

Alqarni M, Myint KZ, Tong Q, Yang P, Bartlow P, Wang L, Feng R, Xie XQ.

Biochem Biophys Res Commun. 2014 Sep 26;452(3):334-9. doi: 10.1016/j.bbrc.2014.08.048. Epub 2014 Aug 19.


Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.

Hu J, Feng Z, Ma S, Zhang Y, Tong Q, Alqarni MH, Gou X, Xie XQ.

J Chem Inf Model. 2016 Jun 27;56(6):1152-63. doi: 10.1021/acs.jcim.5b00739. Epub 2016 May 26.


Molecular biology of cannabinoid receptors.

Abood ME.

Handb Exp Pharmacol. 2005;(168):81-115.


Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis.

Tuccinardi T, Ferrarini PL, Manera C, Ortore G, Saccomanni G, Martinelli A.

J Med Chem. 2006 Feb 9;49(3):984-94.


3D structural model of the G-protein-coupled cannabinoid CB2 receptor.

Xie XQ, Chen JZ, Billings EM.

Proteins. 2003 Nov 1;53(2):307-19.


Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs.

Feng Z, Alqarni MH, Yang P, Tong Q, Chowdhury A, Wang L, Xie XQ.

J Chem Inf Model. 2014 Sep 22;54(9):2483-99. doi: 10.1021/ci5002718. Epub 2014 Sep 5.


Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.

Osman NA, Ligresti A, Klein CD, Allarà M, Rabbito A, Di Marzo V, Abouzid KA, Abadi AH.

Eur J Med Chem. 2016 Oct 21;122:619-634. doi: 10.1016/j.ejmech.2016.07.012. Epub 2016 Jul 9.


hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.

Mercier RW, Pei Y, Pandarinathan L, Janero DR, Zhang J, Makriyannis A.

Chem Biol. 2010 Oct 29;17(10):1132-42. doi: 10.1016/j.chembiol.2010.08.010.


The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner.

Alberich Jordà M, Rayman N, Tas M, Verbakel SE, Battista N, van Lom K, Löwenberg B, Maccarrone M, Delwel R.

Blood. 2004 Jul 15;104(2):526-34. Epub 2004 Mar 23. Erratum in: Blood. 2004 Sep 1;104(5):1252.


3D-QSAR/CoMFA-based structure-affinity/selectivity relationships of aminoalkylindoles in the cannabinoid CB1 and CB2 receptors.

Mella-Raipán J, Hernández-Pino S, Morales-Verdejo C, Pessoa-Mahana D.

Molecules. 2014 Mar 5;19(3):2842-61. doi: 10.3390/molecules19032842.

Supplemental Content

Support Center